>> Looks like a week of angiogenesis news. <<
Of course, the biggest news isn't quite what I was expecting.....
exchange2000.com
Damn, I really wish that ENMD would go away. First they give "it's like a biotech" fodder to the naive generalists, now they taint a sound concept, the inhibition of angiogenesis for cancer therapy. This is what I said yesterday to some friends in email......
"I just finished playing qmakf, ENMD November $30 calls for a quick 2
11/16 to 4 3/4. It should have been 5 1/2 instead of 4 3/4. So, yes,
there are options. But...... why ENMD? Angio I agree, but ENMD is so
primitive and relatively non-competitive. We discuss OSIP, SUGN, AGPH
and REGN often, and these are more leveraged and diversified
business plans. Gotta run the kids to their mom's place. Later. I'm
considering ENMD puts."
Unfortunately, I had not yet bought the puts.
;-(
But..... better news..... as all of you already know, except for those who just found this thread while stumbling aroud SI biotech for the first time, Rman had shorted the sucker in VDXXX. Way to go, Dave!
|
